tetano
Editor, Senior Moderator
J Vet Sci. 2015 Jun 26. [Epub ahead of print]
[h=1]Assessment of the safety and efficacy of low pathogenic avian influenza (H9N2) virus in inactivated oil emulsion vaccine in laying hens.[/h] Shin JH[SUP]1,[/SUP][SUP]2[/SUP], Mo JS[SUP]3[/SUP], Kim JN[SUP]2[/SUP], Mo IP[SUP]2[/SUP], Ha BD[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In Korea, several outbreaks of low pathogenic AI (H9N2) viral infections have been reported on commercial farms with decreased egg production and mortality, resulting in severe economic loss since 1996. To control the H9N2 LPAI endemic situation, since 2007 the Korea Veterinary Authority has permitted the use of the inactivated H9N2 LPAI vaccine. We developed a killed vaccine using a low pathogenic H9N2 AI virus (A/chicken/Korea/ADL0401) and conducted safety and efficacy tests in commercial layer farms, particularly focused on analyzing factors that causes losses to farms including egg production rate, egg abnormality, and feed efficiency. Egg production rate of the control group dramatically declined 5 days after the challenge. There were no changes in feed consumption of all three groups before the challenge, but rates of the control declined afterward. Clinical signs in the vaccinated groups were similar and a slight decline in feed consumption was observed after the challenge but returned to normal pace more rapidly than the control group and commercial layers. Based on all the test results, the safety and efficacy of the vaccine are adequate to provide protection against the AI field infection (H9N2) epidemic in Korea.
PMID: 26119171 [PubMed - as supplied by publisher]
[h=1]Assessment of the safety and efficacy of low pathogenic avian influenza (H9N2) virus in inactivated oil emulsion vaccine in laying hens.[/h] Shin JH[SUP]1,[/SUP][SUP]2[/SUP], Mo JS[SUP]3[/SUP], Kim JN[SUP]2[/SUP], Mo IP[SUP]2[/SUP], Ha BD[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In Korea, several outbreaks of low pathogenic AI (H9N2) viral infections have been reported on commercial farms with decreased egg production and mortality, resulting in severe economic loss since 1996. To control the H9N2 LPAI endemic situation, since 2007 the Korea Veterinary Authority has permitted the use of the inactivated H9N2 LPAI vaccine. We developed a killed vaccine using a low pathogenic H9N2 AI virus (A/chicken/Korea/ADL0401) and conducted safety and efficacy tests in commercial layer farms, particularly focused on analyzing factors that causes losses to farms including egg production rate, egg abnormality, and feed efficiency. Egg production rate of the control group dramatically declined 5 days after the challenge. There were no changes in feed consumption of all three groups before the challenge, but rates of the control declined afterward. Clinical signs in the vaccinated groups were similar and a slight decline in feed consumption was observed after the challenge but returned to normal pace more rapidly than the control group and commercial layers. Based on all the test results, the safety and efficacy of the vaccine are adequate to provide protection against the AI field infection (H9N2) epidemic in Korea.
PMID: 26119171 [PubMed - as supplied by publisher]